check_circleStudy Completed

Wet age-related macular degeneration

Bayer Identifier:

18574

ClinicalTrials.gov Identifier:

NCT03382587

EudraCT Number:

Not Available

EU CT Number:

Not Available
Observational study to assess intravitreal aflibercept injections used in a “treat and extend” regimen in treatment-naïve wet age-related macular degeneration patients

Trial purpose

The purpose of this observational study lies in the analysis of a treat-and-extend injection scheme with intravitreal aflibercept (i.e. injection into the eye), as applied in routine practice in previously untreated patients diagnosed with wet age-related macular degeneration.

Key Participants Requirements

Sex

All

Age

55 - N/A
  • - Diagnosis of wet age-related macular degeneration.
    - No prior therapy for wet age-related macular degeneration.
    - Patients for whom the decision to initiate treatment with IVT-AFL in a T&E regimen was made as per routine clinical practice.
    - Patient age >55 years of age

  • - Participation in an investigational program with therapeutical interventions outside of clinical routine practice.
    - Patients with eye diseases e.g. advanced glaucoma or visually significant cataracts, likely to require surgery during the observation period in the study eye.
    - Concomitant ocular or systemic administration of drugs up to 3 months before commencement of IVT-AFL treatment that could interfere with or potentiate the mechanism of action of aflibercept, including anti-VEGF agents. This includes patients receiving a different anti-VEGF agent for the fellow eye

Trial summary

Enrollment Goal
163
Trial Dates
December 2017 - November 2018
Phase
N/A
Could I Receive a placebo
No
Products
Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)
Accepts Healthy Volunteer
No

Where to participate

StatusInstitutionLocation
Completed
Many LocationsMany Locations, Switzerland

Primary Outcome

  • Mean change from baseline in best-corrected visual acuity in Early Treatment Diabetic Retinopathy Study letters (ETDRS letters)
    mean change in ETDRS letters
    date_rangeTime Frame:
    Baseline and at 12 months

Secondary Outcome

  • Mean change from baseline in best-corrected visual acuity (in Early Treatment Diabetic Retinopathy Study (ETDRS) letters)
    mean change in ETDRS letters
    date_rangeTime Frame:
    Baseline and at 24 months
  • Mean change in best-corrected visual acuity in relation to the number of injections administered
    Numbers of injections will be predefined as categories and analyzed in relation to the BCVA changes
    date_rangeTime Frame:
    Baseline and at 12 months; Baseline and at 24 months
  • Mean interval between injections
    mean interval displayed in weeks or days
    date_rangeTime Frame:
    At 12 and 24 months
  • Reasons for the interval length
    morphology and / or BCVA /other
    date_rangeTime Frame:
    At 12 and 24 months
  • Frequency of disease reactivation
    Disease activity such as hemorrhage, PED, subretinal fluid, cystoid intraretinal fluid, RPE rip assessed at the investigator’s discretion as: none / new or increasing / decreasing / stable
    date_rangeTime Frame:
    Baseline and at 12 months; Baseline and at 24 months
  • Proportion of eyes gaining or losing ≥ 15 Early Treatment Diabetic Retinopathy Study letters compared to baseline
    Proportion evaluated as percentage (%) of eyes
    date_rangeTime Frame:
    Baseline and at 12 months; Baseline and at 24 months
  • Mean changes from baseline in central retinal thickness (CRT)
    micro meter (µm)
    date_rangeTime Frame:
    Baseline and at 3 months; Baseline and at 12 months; Baseline and 24 months
  • Changes from baseline in retinal fluid
    intraretinal or subretinal fluid or pigment epithelial detachment (PED)
    date_rangeTime Frame:
    Baseline and at 12 months; Baseline and at 24 months
  • Reasons for termination of therapy (including subsequent therapy at time of discontinuation)
    Categorized into typical reasons for discontinuation such as e.g. death, lost to Follow-up, withdrawal of informed consent, change of treatment regimen, discontinuation of IVT-AFL treatment, interfering surgery or treatment, adverse event, other
    date_rangeTime Frame:
    At 12 and 24 months
  • Severity of disease reactivation
    Severity of disease reactivation assessed at the investigator’s discretion as: no new disease activity / mild / severe
    date_rangeTime Frame:
    Baseline and at 12 months; Baseline and at 24 months

Trial design

An observational study to assess the use of intravitreal aflibercept injections in a routine “treat and extend” regimen in treatment-naïve patients diagnosed with wet age-related macular degeneration
Trial Type
Observational
Intervention Type
Drug
Trial Purpose
N/A
Allocation
N/A
Blinding
N/A
Assignment
N/A
Trial Arms
N/A

Additional Information

Click here to find results for studies related to Bayer Healthcare products.